Bivirkningsprofilen var ens i alle de respektive studier med voksne; behandlingsnaive patienter (APV30002) og patienter, der tidligere har været behandlet med proteasehæmmere (dosering 2 gange daglig, APV30003).
The adverse reaction profile was similar across all the respective adult studies: antiretroviral naïve (APV30002) and protease inhibitor experienced (twice daily dosing, APV30003) patient populations.